search
Back to results

The Women In Steady Exercise Research (WISER) Survivor Trial (WISER Survivor)

Primary Purpose

Lymphedema

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Exercise Intervention
Weight Loss Intervention
Sponsored by
Milton S. Hershey Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Lymphedema focused on measuring Lymphedema, Strength training intervention, Weight loss intervention, Breast cancer recurrence, Cost Effectiveness

Eligibility Criteria

undefined - 80 Years (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • breast cancer survivor
  • overweight or obese (BMI of 25 or greater)
  • must have breast cancer related lymphedema
  • at least 6 months post-treatment (e.g. surgery, chemotherapy, or radiotherapy) but there will be no upper limit on time elapsed from diagnosis
  • the eligible age range will have no lower limit.
  • currently free of cancer

Exclusion Criteria:

  • medical conditions or medications that would prohibit participation in an exercise program or would negatively impact our ability to test our primary aims
  • inability to walk for 6 minutes unaided
  • extremely obese (body mass index greater or equal to 50 kg/m2)
  • plans for additional (e.g. curative or reconstructive) surgery during the study period
  • self-report of weight-lifting within the past year
  • already engaging in 3 or more times weekly aerobic activity of moderate intensity
  • planning to move away from the area over the next year
  • current use of weight loss medication (OTC or prescription)
  • self-report of alcohol or substance abuse within the past 12 months, including at-risk drinking (current consumption of more than 14 alcoholic drinks per week)
  • weight loss of greater than 10 % in the past 3 months
  • history of bariatric surgery
  • women who are pregnant

Sites / Locations

  • The Penn TREC Survivorship Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

Experimental

Experimental

Arm Label

Lymphedema Care Only

Exercise only

Weight loss only

Exercise and Weight loss combined

Arm Description

All 4 groups receive lymphedema care as follows: 2 custom fitted compression garments (baseline and 6 months) evaluations for flare-ups at request (and at each measurement time point) lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions.

The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.

The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.

Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.

Outcomes

Primary Outcome Measures

Percent interlimb difference, change over 12 months.
Arm volumes for affected and unaffected limbs will be measured by perometry and the % difference will be determined at baseline and 12 months. the absolute percentage point difference of differences (% interlimb difference at 12 months minus % interlimb difference at baseline) will be the primary outcome

Secondary Outcome Measures

Clinical Lymphedema Events
Flare-ups and cellulitic infections (number and type recorded)
Clinical Evaluation Score for Lymphedema
Standardized clinical evaluation survey completed by certified lymphatic therapists
Norman Lymphedema Survey
Thirteen symptoms, recorded within a standardized survey (Norman Lymphedema Survey)
Weight loss
body weight loss over 12 months
Biomarkers: Estradiol
circulating estradiol levels in the blood
Biomarkers: Testosterone
circulating testosterone levels in the blood
Biomarkers - Sex Hormone Binding Globulin
circulating sex hormone binding globulin levels in the blood
Inflammation: Interleukin six
Circulating interleukin six levels in the blood
Inflammation: C reactive protein
Circulating c reactive protein levels in the blood
Adiponectin
circulating Adiponectin levels in the blood
Leptin
circulating leptin levels in the blood
F2-isoprostanes
circulating F2-isoprostane levels in the blood
Insulin
circulating insulin levels in the blood
Glucose
circulating glucose levels in the blood
insulin like growth factor one
circulating levels of insulin like growth factor one in the blood
insulin like growth factor binding protein three
circulating levels of insulin like growth factor binding protein three in the blood
Upper limb lymphedema twenty seven
27 item survey on lymphedema quality of life
body image and relationship survey
32 item survey on body image specifically developed for breast cancer survivors

Full Information

First Posted
January 18, 2012
Last Updated
October 6, 2022
Sponsor
Milton S. Hershey Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01515124
Brief Title
The Women In Steady Exercise Research (WISER) Survivor Trial
Acronym
WISER Survivor
Official Title
The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
January 2012 (Actual)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Milton S. Hershey Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
WISER Survivor is a one year weight loss and exercise study for sedentary breast cancer survivors who are overweight or obese with breast cancer related lymphedema. There will be four groups in this trial: exercise only, weight loss only, exercise and weight-loss combined, and a control group. The primary purpose of this study is to test the effects of these interventions on clinical lymphedema outcomes. Secondary outcomes include weight loss, breast cancer related biomarkers, and quality of life. To the extent that funding will be available, participants will be followed long term to examine effects on recurrence and mortality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphedema
Keywords
Lymphedema, Strength training intervention, Weight loss intervention, Breast cancer recurrence, Cost Effectiveness

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
All participants asked at the start of each measurement encounter not to inform measurement staff of their randomization group status. All measurement staff asked to guess group status at end of each measurement encounter. Patterns of responses beyond chance result in corrective action to improve masking (e.g.; requests from PI for participants to mask group status)
Allocation
Randomized
Enrollment
450 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lymphedema Care Only
Arm Type
No Intervention
Arm Description
All 4 groups receive lymphedema care as follows: 2 custom fitted compression garments (baseline and 6 months) evaluations for flare-ups at request (and at each measurement time point) lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions.
Arm Title
Exercise only
Arm Type
Experimental
Arm Description
The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
Arm Title
Weight loss only
Arm Type
Experimental
Arm Description
The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
Arm Title
Exercise and Weight loss combined
Arm Type
Experimental
Arm Description
Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
Intervention Type
Behavioral
Intervention Name(s)
Exercise Intervention
Intervention Description
The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
Intervention Type
Behavioral
Intervention Name(s)
Weight Loss Intervention
Intervention Description
The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
Primary Outcome Measure Information:
Title
Percent interlimb difference, change over 12 months.
Description
Arm volumes for affected and unaffected limbs will be measured by perometry and the % difference will be determined at baseline and 12 months. the absolute percentage point difference of differences (% interlimb difference at 12 months minus % interlimb difference at baseline) will be the primary outcome
Time Frame
Baseline and 12 months
Secondary Outcome Measure Information:
Title
Clinical Lymphedema Events
Description
Flare-ups and cellulitic infections (number and type recorded)
Time Frame
Data collected over the 12 month follow-up, with events collected as reported
Title
Clinical Evaluation Score for Lymphedema
Description
Standardized clinical evaluation survey completed by certified lymphatic therapists
Time Frame
Baseline and 12 months
Title
Norman Lymphedema Survey
Description
Thirteen symptoms, recorded within a standardized survey (Norman Lymphedema Survey)
Time Frame
Baseline and 12 months
Title
Weight loss
Description
body weight loss over 12 months
Time Frame
Baseline and 12 months
Title
Biomarkers: Estradiol
Description
circulating estradiol levels in the blood
Time Frame
baseline and 12 months
Title
Biomarkers: Testosterone
Description
circulating testosterone levels in the blood
Time Frame
baseline and 12 months
Title
Biomarkers - Sex Hormone Binding Globulin
Description
circulating sex hormone binding globulin levels in the blood
Time Frame
baseline and 12 months
Title
Inflammation: Interleukin six
Description
Circulating interleukin six levels in the blood
Time Frame
baseline and 12 months
Title
Inflammation: C reactive protein
Description
Circulating c reactive protein levels in the blood
Time Frame
baseline and 12 months
Title
Adiponectin
Description
circulating Adiponectin levels in the blood
Time Frame
baseline and 12 months
Title
Leptin
Description
circulating leptin levels in the blood
Time Frame
baseline and 12 months
Title
F2-isoprostanes
Description
circulating F2-isoprostane levels in the blood
Time Frame
baseline and 12 months
Title
Insulin
Description
circulating insulin levels in the blood
Time Frame
baseline and 12 months
Title
Glucose
Description
circulating glucose levels in the blood
Time Frame
baseline and 12 months
Title
insulin like growth factor one
Description
circulating levels of insulin like growth factor one in the blood
Time Frame
baseline and 12 months
Title
insulin like growth factor binding protein three
Description
circulating levels of insulin like growth factor binding protein three in the blood
Time Frame
baseline and 12 months
Title
Upper limb lymphedema twenty seven
Description
27 item survey on lymphedema quality of life
Time Frame
baseline and 12 months
Title
body image and relationship survey
Description
32 item survey on body image specifically developed for breast cancer survivors
Time Frame
baseline and 12 months
Other Pre-specified Outcome Measures:
Title
breast cancer recurrence
Description
participants will be followed for breast cancer recurrence
Time Frame
10 years post trial
Title
mortality
Description
participants will be followed for mortality
Time Frame
10 years post trial

10. Eligibility

Sex
Female
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: breast cancer survivor overweight or obese (BMI of 25 or greater) must have breast cancer related lymphedema at least 6 months post-treatment (e.g. surgery, chemotherapy, or radiotherapy) but there will be no upper limit on time elapsed from diagnosis the eligible age range will have no lower limit. currently free of cancer Exclusion Criteria: medical conditions or medications that would prohibit participation in an exercise program or would negatively impact our ability to test our primary aims inability to walk for 6 minutes unaided extremely obese (body mass index greater or equal to 50 kg/m2) plans for additional (e.g. curative or reconstructive) surgery during the study period self-report of weight-lifting within the past year already engaging in 3 or more times weekly aerobic activity of moderate intensity planning to move away from the area over the next year current use of weight loss medication (OTC or prescription) self-report of alcohol or substance abuse within the past 12 months, including at-risk drinking (current consumption of more than 14 alcoholic drinks per week) weight loss of greater than 10 % in the past 3 months history of bariatric surgery women who are pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathryn H. Schmitz, MPH,PhD
Organizational Affiliation
Penn State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Penn TREC Survivorship Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
20052559
Citation
Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010 Jun;4(2):87-100. doi: 10.1007/s11764-009-0110-5. Epub 2010 Jan 6. Erratum In: J Cancer Surviv. 2011 Mar;5(1):112.
Results Reference
background
Citation
Hewitt M, Greenfield, S., Stovall, E. , ed. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, D.C.: National Academies Press; 2006.
Results Reference
background
PubMed Identifier
19403886
Citation
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009 Jun 10;27(17):2758-65. doi: 10.1200/JCO.2008.20.8983. Epub 2009 Apr 29.
Results Reference
background
PubMed Identifier
19474385
Citation
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
Results Reference
background
PubMed Identifier
17691908
Citation
Hursting SD, Lashinger LM, Colbert LH, Rogers CJ, Wheatley KW, Nunez NP, Mahabir S, Barrett JC, Forman MR, Perkins SN. Energy balance and carcinogenesis: underlying pathways and targets for intervention. Curr Cancer Drug Targets. 2007 Aug;7(5):484-91. doi: 10.2174/156800907781386623.
Results Reference
background
PubMed Identifier
15914748
Citation
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 May 25;293(20):2479-86. doi: 10.1001/jama.293.20.2479.
Results Reference
background
PubMed Identifier
19123472
Citation
Friedenreich CM, Gregory J, Kopciuk KA, Mackey JR, Courneya KS. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer. 2009 Apr 15;124(8):1954-62. doi: 10.1002/ijc.24155.
Results Reference
background
PubMed Identifier
18711185
Citation
Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, Gilliland FD, Baumgartner RN, Baumgartner KB, Bernstein L. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol. 2008 Aug 20;26(24):3958-64. doi: 10.1200/JCO.2007.15.9822.
Results Reference
background
PubMed Identifier
15779870
Citation
Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest. 2005;23(1):76-83.
Results Reference
background
PubMed Identifier
19064976
Citation
Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009 Jan 20;27(3):390-7. doi: 10.1200/JCO.2008.17.9291. Epub 2008 Dec 8.
Results Reference
background
PubMed Identifier
17071198
Citation
Francis WP, Abghari P, Du W, Rymal C, Suna M, Kosir MA. Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg. 2006 Nov;192(5):636-9. doi: 10.1016/j.amjsurg.2006.08.018. No abstract available.
Results Reference
background
PubMed Identifier
10649254
Citation
Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000 Feb 1;88(3):608-14. doi: 10.1002/(sici)1097-0142(20000201)88:33.0.co;2-k.
Results Reference
background
PubMed Identifier
16514477
Citation
Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006 Apr;13(4):491-500. doi: 10.1245/ASO.2006.05.013. Epub 2006 Mar 2.
Results Reference
background
PubMed Identifier
9874397
Citation
Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998 Dec 15;83(12 Suppl American):2776-81. doi: 10.1002/(sici)1097-0142(19981215)83:12b+3.0.co;2-v.
Results Reference
background
PubMed Identifier
19289624
Citation
Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, Perkins GH, Elting LS. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009 Apr 20;27(12):2007-14. doi: 10.1200/JCO.2008.18.3517. Epub 2009 Mar 16.
Results Reference
background
PubMed Identifier
2760668
Citation
Maunsell E, Brisson J, Deschenes L. Psychological distress after initial treatment for breast cancer: a comparison of partial and total mastectomy. J Clin Epidemiol. 1989;42(8):765-71. doi: 10.1016/0895-4356(89)90074-7.
Results Reference
background
PubMed Identifier
9874404
Citation
Passik SD, McDonald MV. Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Cancer. 1998 Dec 15;83(12 Suppl American):2817-20. doi: 10.1002/(sici)1097-0142(19981215)83:12b+3.0.co;2-2.
Results Reference
background
PubMed Identifier
1470692
Citation
Sneeuw KC, Aaronson NK, Yarnold JR, Broderick M, Regan J, Ross G, Goddard A. Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 2. Relationship with psychosocial functioning. Radiother Oncol. 1992 Nov;25(3):160-6. doi: 10.1016/0167-8140(92)90262-s.
Results Reference
background
PubMed Identifier
9201739
Citation
Carter BJ. Women's experiences of lymphedema. Oncol Nurs Forum. 1997 Jun;24(5):875-82.
Results Reference
background
PubMed Identifier
19001331
Citation
Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR. Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol. 2008 Dec 10;26(35):5689-96. doi: 10.1200/JCO.2008.16.4731. Epub 2008 Nov 10.
Results Reference
background
PubMed Identifier
15968692
Citation
McWayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer. 2005 Aug 1;104(3):457-66. doi: 10.1002/cncr.21195.
Results Reference
background
Citation
Cheville A. Patient perceptions of lymphedema maintenance therapy: is the cure worse than the condition? In: American Academy of Physical Medicine and Rehabilitation Orlando, FL; 2002.
Results Reference
background
PubMed Identifier
19509430
Citation
Mak SS, Yeo W, Lee YM, Tse SM, Ho FP, Zee B, Chan E. Risk factors for the initiation and aggravation of lymphoedema after axillary lymph node dissection for breast cancer. Hong Kong Med J. 2009 Jun;15(3 Suppl 4):8-12. No abstract available.
Results Reference
background
PubMed Identifier
19427748
Citation
Bar Ad V, Cheville A, Solin LJ, Dutta P, Both S, Harris EE. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):85-90. doi: 10.1016/j.ijrobp.2009.01.024.
Results Reference
background
PubMed Identifier
20564063
Citation
Cheville AL, Almoza M, Courmier JN, Basford JR. A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema. Cancer. 2010 Aug 1;116(15):3722-31. doi: 10.1002/cncr.25068.
Results Reference
background
PubMed Identifier
15812652
Citation
Ridner SH. Quality of life and a symptom cluster associated with breast cancer treatment-related lymphedema. Support Care Cancer. 2005 Nov;13(11):904-11. doi: 10.1007/s00520-005-0810-y. Epub 2005 Apr 6.
Results Reference
background
PubMed Identifier
19147865
Citation
Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009 Jan-Feb;59(1):8-24. doi: 10.3322/caac.20001.
Results Reference
background
PubMed Identifier
19694769
Citation
Karppelin M, Siljander T, Vuopio-Varkila J, Kere J, Huhtala H, Vuento R, Jussila T, Syrjanen J. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clin Microbiol Infect. 2010 Jun;16(6):729-34. doi: 10.1111/j.1469-0691.2009.02906.x. Epub 2009 Aug 20.
Results Reference
background
PubMed Identifier
20016295
Citation
Schmitz KH. Balancing lymphedema risk: exercise versus deconditioning for breast cancer survivors. Exerc Sport Sci Rev. 2010 Jan;38(1):17-24. doi: 10.1097/JES.0b013e3181c5cd5a.
Results Reference
background
PubMed Identifier
17624588
Citation
Cheema B, Gaul CA, Lane K, Fiatarone Singh MA. Progressive resistance training in breast cancer: a systematic review of clinical trials. Breast Cancer Res Treat. 2008 May;109(1):9-26. doi: 10.1007/s10549-007-9638-0. Epub 2007 Jul 12.
Results Reference
background
PubMed Identifier
19675330
Citation
Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan CJ, Williams-Smith CT, Greene QP. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009 Aug 13;361(7):664-73. doi: 10.1056/NEJMoa0810118.
Results Reference
background
PubMed Identifier
19543691
Citation
Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009 Nov;58(11):727-36. doi: 10.1007/s00011-009-0060-4. Epub 2009 Jun 19.
Results Reference
background
PubMed Identifier
17823909
Citation
Shaw C, Mortimer P, Judd PA. A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema. Cancer. 2007 Oct 15;110(8):1868-74. doi: 10.1002/cncr.22994.
Results Reference
background
PubMed Identifier
17393377
Citation
Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer. 2007 May 15;109(10):1949-56. doi: 10.1002/cncr.22638.
Results Reference
background
PubMed Identifier
16030100
Citation
Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1672-80. doi: 10.1158/1055-9965.EPI-04-0736.
Results Reference
background
PubMed Identifier
18250341
Citation
Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):379-86. doi: 10.1158/1055-9965.EPI-07-0771. Epub 2008 Feb 4.
Results Reference
background
PubMed Identifier
17557947
Citation
Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, Al-Delaimy WK, Thomson CA, Kealey S, Hajek R, Parker BA, Newman VA, Caan B, Rock CL. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007 Jun 10;25(17):2345-51. doi: 10.1200/JCO.2006.08.6819.
Results Reference
background
PubMed Identifier
15684320
Citation
Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005 Mar 1;23(7):1370-8. doi: 10.1200/JCO.2005.01.079. Epub 2005 Jan 31.
Results Reference
background
PubMed Identifier
16541317
Citation
Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, Habel L, Jones L, Newman VA, Rock CL, Slattery ML, Stefanick ML, Sternfeld B, Thomson CA, Pierce JP. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat. 2006 Sep;99(1):47-57. doi: 10.1007/s10549-006-9179-y. Epub 2006 Mar 16.
Results Reference
background
PubMed Identifier
19139422
Citation
Daniell HW. Weight loss after breast cancer diagnosis may not improve prognosis. J Clin Oncol. 2009 Feb 10;27(5):829-30; author reply 830-1. doi: 10.1200/JCO.2008.20.5294. Epub 2009 Jan 12. No abstract available.
Results Reference
background
PubMed Identifier
17179478
Citation
Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006 Dec 20;98(24):1767-76. doi: 10.1093/jnci/djj494.
Results Reference
background
PubMed Identifier
17635889
Citation
Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007 Jul 18;298(3):289-98. doi: 10.1001/jama.298.3.289.
Results Reference
background
PubMed Identifier
19124513
Citation
Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, Dipietro L, Mayne ST, Yu H. Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):306-13. doi: 10.1158/1055-9965.EPI-08-0531.
Results Reference
background
PubMed Identifier
18281663
Citation
Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008 Feb 20;26(6):907-12. doi: 10.1200/JCO.2007.12.7357.
Results Reference
background
PubMed Identifier
12917202
Citation
Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):721-7.
Results Reference
background
PubMed Identifier
15772062
Citation
Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol (1985). 2005 Apr;98(4):1534-40. doi: 10.1152/japplphysiol.00566.2004.
Results Reference
background
PubMed Identifier
15922556
Citation
Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Martin BS, Mackey JR. Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun. 2005 Sep;19(5):381-8. doi: 10.1016/j.bbi.2005.04.001.
Results Reference
background
PubMed Identifier
18563595
Citation
Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis. 2009;26(1):51-60. doi: 10.1007/s10585-008-9176-0. Epub 2008 Jun 18.
Results Reference
background
PubMed Identifier
18323413
Citation
Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA, Al-Delaimy WK, Stanczyk FZ, Pierce JP; Women's Healthy Eating and Living Study Group. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):614-20. doi: 10.1158/1055-9965.EPI-07-0761. Epub 2008 Mar 6.
Results Reference
background
PubMed Identifier
19470939
Citation
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009 Jul 20;27(21):3437-44. doi: 10.1200/JCO.2008.18.9068. Epub 2009 May 26.
Results Reference
background
PubMed Identifier
11689595
Citation
Ozet A, Arpaci F, Yilmaz MI, Ayta H, Ozturk B, Komurcu S, Yavuz AA, Tezcan Y, Acikel C. Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol. 2001 Sep;31(9):424-7. doi: 10.1093/jjco/hye097.
Results Reference
background
PubMed Identifier
17908478
Citation
Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, Sun Y, Wu Q, Chen L. Adipocytokines and breast cancer risk. Chin Med J (Engl). 2007 Sep 20;120(18):1592-6.
Results Reference
background
PubMed Identifier
19380446
Citation
Dai Q, Gao YT, Shu XO, Yang G, Milne G, Cai Q, Wen W, Rothman N, Cai H, Li H, Xiang Y, Chow WH, Zheng W. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol. 2009 May 20;27(15):2482-8. doi: 10.1200/JCO.2008.19.7970. Epub 2009 Apr 20.
Results Reference
background
PubMed Identifier
18628423
Citation
Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1719-22. doi: 10.1158/1055-9965.EPI-07-0654.
Results Reference
background
PubMed Identifier
14763914
Citation
Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol. 2004 Feb;150(2):161-71. doi: 10.1530/eje.0.1500161.
Results Reference
background
PubMed Identifier
18401703
Citation
Pierce BL, Neuhouser ML, Wener MH, Bernstein L, Baumgartner RN, Ballard-Barbash R, Gilliland FD, Baumgartner KB, Sorensen B, McTiernan A, Ulrich CM. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat. 2009 Mar;114(1):155-67. doi: 10.1007/s10549-008-9985-5. Epub 2008 Apr 10.
Results Reference
background
PubMed Identifier
15070939
Citation
You T, Berman DM, Ryan AS, Nicklas BJ. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab. 2004 Apr;89(4):1739-46. doi: 10.1210/jc.2003-031310. Erratum In: J Clin Endocrinol Metab.2004 Jun;89(6):2972.
Results Reference
background
PubMed Identifier
15860436
Citation
Thomson CA, Giuliano AR, Shaw JW, Rock CL, Ritenbaugh CK, Hakim IA, Hollenbach KA, Alberts DS, Pierce JP. Diet and biomarkers of oxidative damage in women previously treated for breast cancer. Nutr Cancer. 2005;51(2):146-54. doi: 10.1207/s15327914nc5102_4.
Results Reference
background
PubMed Identifier
16552400
Citation
Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, Clavel-Chapelon F, van Gils CH, van Noord PA, Peeters PH, Bueno-de-Mesquita HB, Nagel G, Linseisen J, Lahmann PH, Boeing H, Palli D, Sacerdote C, Panico S, Tumino R, Sieri S, Dorronsoro M, Quiros JR, Navarro CA, Barricarte A, Tormo MJ, Gonzalez CA, Overvad K, Paaske Johnsen S, Olsen A, Tjonneland A, Travis R, Allen N, Bingham S, Khaw KT, Stattin P, Trichopoulou A, Kalapothaki V, Psaltopoulou T, Casagrande C, Riboli E, Kaaks R. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond). 2006 Nov;30(11):1623-31. doi: 10.1038/sj.ijo.0803324. Epub 2006 Mar 21.
Results Reference
background
PubMed Identifier
17560335
Citation
Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007 Jun;11(6):539-54. doi: 10.1016/j.ccr.2007.04.017.
Results Reference
background
PubMed Identifier
19520599
Citation
Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev. 2009 Jun;20(3):193-201. doi: 10.1016/j.cytogfr.2009.05.007. Epub 2009 Jun 10.
Results Reference
background
PubMed Identifier
17826066
Citation
Hieken TJ, Cheregi J, Farolan M, Kim J, Velasco JM. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. Am J Surg. 2007 Oct;194(4):504-6. doi: 10.1016/j.amjsurg.2007.07.002.
Results Reference
background
PubMed Identifier
15646833
Citation
Nicolini A, Campani D, Miccoli P, Spinelli C, Carpi A, Menicagli M, Ferrari P, Gadducci G, Rossi G, Fini M, Giavaresi G, Bonazzi V, Giardino R. Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study. Int J Biol Markers. 2004 Oct-Dec;19(4):275-81. doi: 10.1177/172460080401900404.
Results Reference
background
PubMed Identifier
19549711
Citation
Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009 Oct;20(10):1639-46. doi: 10.1093/annonc/mdp062. Epub 2009 Jun 23.
Results Reference
background
PubMed Identifier
18936974
Citation
Shivakumar S, Prabhakar BT, Jayashree K, Rajan MG, Salimath BP. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol. 2009 Apr;135(4):627-36. doi: 10.1007/s00432-008-0497-9. Epub 2008 Oct 21.
Results Reference
background
PubMed Identifier
19996223
Citation
Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F. Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res. 2009 Dec 15;15(24):7652-7657. doi: 10.1158/1078-0432.CCR-09-1493.
Results Reference
background
PubMed Identifier
20086246
Citation
Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr, Ryeom S. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010 Jun 3;115(22):4605-13. doi: 10.1182/blood-2009-09-242065. Epub 2010 Jan 19.
Results Reference
background
PubMed Identifier
19771507
Citation
Speck RM, Gross CR, Hormes JM, Ahmed RL, Lytle LA, Hwang WT, Schmitz KH. Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema. Breast Cancer Res Treat. 2010 Jun;121(2):421-30. doi: 10.1007/s10549-009-0550-7. Epub 2009 Sep 22.
Results Reference
background
PubMed Identifier
20552814
Citation
Hormes JM, Bryan C, Lytle LA, Gross CR, Ahmed RL, Troxel AB, Schmitz KH. Impact of lymphedema and arm symptoms on quality of life in breast cancer survivors. Lymphology. 2010 Mar;43(1):1-13.
Results Reference
background
PubMed Identifier
12081052
Citation
Weiss JM, Spray BJ. The effect of complete decongestive therapy on the quality of life of patients with peripheral lymphedema. Lymphology. 2002 Jun;35(2):46-58.
Results Reference
background
PubMed Identifier
17577017
Citation
Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ; ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007 Sep 1;25(25):3991-4008. doi: 10.1200/JCO.2007.10.9777. Epub 2007 Jun 18.
Results Reference
background
PubMed Identifier
19171204
Citation
Schmitz KH, Troxel AB, Cheville A, Grant LL, Bryan CJ, Gross CR, Lytle LA, Ahmed RL. Physical Activity and Lymphedema (the PAL trial): assessing the safety of progressive strength training in breast cancer survivors. Contemp Clin Trials. 2009 May;30(3):233-45. doi: 10.1016/j.cct.2009.01.001. Epub 2009 Jan 8.
Results Reference
background
PubMed Identifier
16568409
Citation
Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. Cancer. 2006 May 1;106(9):2076-83. doi: 10.1002/cncr.21829.
Results Reference
background
Citation
Derbas J, Vetter, M., Volger, S., Khan, Z., Panigrahi, E., Tsai, A.G., Sarwer, D.B., Wadden, T.A. Improving Weight Management in Primary Care Practice: A Possible Role for Auxiliary Health Professionals Collaborating with Primary Care Physicians. Obesity and Weight Management 2009;5:210-5.
Results Reference
background
Citation
Klemp JK CS, Papsek S, et al. . Feasibility of a diet, exercise, and behavior modification intervention for post-menopausal breast cancer survivors. . Cancer Res 2009;67(24):557S.
Results Reference
background
PubMed Identifier
12903011
Citation
Cheville AL, McGarvey CL, Petrek JA, Russo SA, Thiadens SR, Taylor ME. The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol. 2003 Jul;13(3):214-25. doi: 10.1016/S1053-4296(03)00038-9.
Results Reference
background
PubMed Identifier
19516160
Citation
Rogerino A, Grant LL, Wilcox H 3rd, Schmitz KH. Geographic recruitment of breast cancer survivors into community-based exercise interventions. Med Sci Sports Exerc. 2009 Jul;41(7):1413-20. doi: 10.1249/MSS.0b013e31819af871.
Results Reference
background
Citation
NLN Medical Advisory Commitee. Position Statement of the National Lymphedema Network. Topic: Lymphedema Risk Reduction Practices. In; 2005:1-2.
Results Reference
background
Citation
Földi M, Földi, E., Strössenreuther, R.H.K., Kubik, S. Foldi's Textbook of Lymphology for Physicians and Lymphedema Therapists: For Physicians and Lymphedema Therapists. 2nd ed. Munich: Elsevier,Urban&FischerVerlag; 2006.
Results Reference
background
PubMed Identifier
9569518
Citation
Cornish BH, Thomas BJ, Ward LC. Effect of temperature and sweating on bioimpedance measurements. Appl Radiat Isot. 1998 May-Jun;49(5-6):475-6. doi: 10.1016/s0969-8043(97)00057-2.
Results Reference
background
Citation
Consensus Document on the Management of Cellulitis in Lymphoedema. British Lymphology Society and the Lymphedema Support Network, 2007. (Accessed October 26, 2009, at http://www.lymphoedema.org/lsn/consensus_on_cellulitis_dec_06.pdf.)
Results Reference
background
Citation
Topic: Training of Lymphedema Therapists. National Lymphedema Network National Advisory Committee, 2005. (Accessed Access Date: September 17, 2008, 2008, at http://www.lymphnet.org/lymphedemaFAQs/positionPapers.htm.)
Results Reference
background
PubMed Identifier
9215977
Citation
Stanton AW, Northfield JW, Holroyd B, Mortimer PS, Levick JR. Validation of an optoelectronic limb volumeter (Perometer). Lymphology. 1997 Jun;30(2):77-97.
Results Reference
background
PubMed Identifier
8980428
Citation
Tierney S, Aslam M, Rennie K, Grace P. Infrared optoelectronic volumetry, the ideal way to measure limb volume. Eur J Vasc Endovasc Surg. 1996 Nov;12(4):412-7. doi: 10.1016/s1078-5884(96)80005-0.
Results Reference
background
PubMed Identifier
10943582
Citation
Labs KH, Tschoepl M, Gamba G, Aschwanden M, Jaeger KA. The reliability of leg circumference assessment: a comparison of spring tape measurements and optoelectronic volumetry. Vasc Med. 2000;5(2):69-74. doi: 10.1177/1358836X0000500202.
Results Reference
background
Citation
Coutts F, Grainger, A, Bulley, C. Perometer (400T) measurement of lower limb volume: Development of a standardised protocol. Physiotherapy 2007;93(Suppl 1):S670.
Results Reference
background
PubMed Identifier
1015603
Citation
Revill SI, Robinson JO, Rosen M, Hogg MI. The reliability of a linear analogue for evaluating pain. Anaesthesia. 1976 Nov;31(9):1191-8. doi: 10.1111/j.1365-2044.1976.tb11971.x.
Results Reference
background
PubMed Identifier
686873
Citation
Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978 Aug;37(4):378-81. doi: 10.1136/ard.37.4.378.
Results Reference
background
PubMed Identifier
6226917
Citation
Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983 Sep;17(1):45-56. doi: 10.1016/0304-3959(83)90126-4.
Results Reference
background
PubMed Identifier
11380275
Citation
Norman SA, Miller LT, Erikson HB, Norman MF, McCorkle R. Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer. Phys Ther. 2001 Jun;81(6):1192-205.
Results Reference
background
Citation
Fleck S, Kraemer W. Designing resistance training programs. 2nd ed. Champaign, IL: Human Kinetics; 1997.
Results Reference
background
PubMed Identifier
4632004
Citation
Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J. 1973 Apr;85(4):546-62. doi: 10.1016/0002-8703(73)90502-4. No abstract available.
Results Reference
background
PubMed Identifier
6720550
Citation
Foster C, Jackson AS, Pollock ML, Taylor MM, Hare J, Sennett SM, Rod JL, Sarwar M, Schmidt DH. Generalized equations for predicting functional capacity from treadmill performance. Am Heart J. 1984 Jun;107(6):1229-34. doi: 10.1016/0002-8703(84)90282-5. No abstract available.
Results Reference
background
PubMed Identifier
7664343
Citation
Hartwig JH, Bokoch GM, Carpenter CL, Janmey PA, Taylor LA, Toker A, Stossel TP. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell. 1995 Aug 25;82(4):643-53. doi: 10.1016/0092-8674(95)90036-5.
Results Reference
background
PubMed Identifier
11718683
Citation
Morales CR, Terry ES, Zackert WE, Montine TJ, Morrow JD. Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay. Clin Chim Acta. 2001 Dec;314(1-2):93-9. doi: 10.1016/s0009-8981(01)00637-4.
Results Reference
background
PubMed Identifier
10933275
Citation
Subar AF, Midthune D, Kulldorff M, Brown CC, Thompson FE, Kipnis V, Schatzkin A. Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. Am J Epidemiol. 2000 Aug 1;152(3):279-86. doi: 10.1093/aje/152.3.279.
Results Reference
background
PubMed Identifier
11744511
Citation
Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt S, McIntosh A, Rosenfeld S. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires : the Eating at America's Table Study. Am J Epidemiol. 2001 Dec 15;154(12):1089-99. doi: 10.1093/aje/154.12.1089.
Results Reference
background
PubMed Identifier
2318100
Citation
Kriska AM, Knowler WC, LaPorte RE, Drash AL, Wing RR, Blair SN, Bennett PH, Kuller LH. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care. 1990 Apr;13(4):401-11. doi: 10.2337/diacare.13.4.401.
Results Reference
background
Citation
Launois R, Mègnigbêto, A.C., Pocquet, K.,Alliot, F. A specific quality of life scale in upper limb lymphedema: the ULL-27 questionnaire. Lymphology 2002;35(Suppl):181-7.
Results Reference
background
PubMed Identifier
18323550
Citation
Hormes JM, Lytle LA, Gross CR, Ahmed RL, Troxel AB, Schmitz KH. The body image and relationships scale: development and validation of a measure of body image in female breast cancer survivors. J Clin Oncol. 2008 Mar 10;26(8):1269-74. doi: 10.1200/JCO.2007.14.2661.
Results Reference
background
Citation
Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 1979;6:65-70.
Results Reference
background
Citation
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802.
Results Reference
background
Citation
Singer J, Willett J. Applied Longitudinal Data Analysis. New York: Oxford University Press; 2003.
Results Reference
background
Citation
Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. Hoboken, New Jersey: Wiley; 2004.
Results Reference
background
Citation
Troxel A. An index of local sensitivity to nonignorability. Statistica Sinica 2004;14:1221-37.
Results Reference
background
PubMed Identifier
15909292
Citation
Ma G, Troxel AB, Heitjan DF. An index of local sensitivity to nonignorable drop-out in longitudinal modelling. Stat Med. 2005 Jul 30;24(14):2129-50. doi: 10.1002/sim.2107.
Results Reference
background
PubMed Identifier
18695137
Citation
Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83. doi: 10.1093/jnci/djn233. Epub 2008 Aug 11.
Results Reference
background
PubMed Identifier
19445432
Citation
Warren M, Schmitz KH. Safety of strength training in premenopausal women: musculoskeletal injuries from a two-year randomized trial. Am J Health Promot. 2009 May-Jun;23(5):309-14. doi: 10.4278/ajhp.07081584.
Results Reference
background
PubMed Identifier
9710864
Citation
Powell KE, Heath GW, Kresnow MJ, Sacks JJ, Branche CM. Injury rates from walking, gardening, weightlifting, outdoor bicycling, and aerobics. Med Sci Sports Exerc. 1998 Aug;30(8):1246-9. doi: 10.1097/00005768-199808000-00010.
Results Reference
background
PubMed Identifier
31415063
Citation
Schmitz KH, Troxel AB, Dean LT, DeMichele A, Brown JC, Sturgeon K, Zhang Z, Evangelisti M, Spinelli B, Kallan MJ, Denlinger C, Cheville A, Winkels RM, Chodosh L, Sarwer DB. Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors: The WISER Survivor Randomized Clinical Trial. JAMA Oncol. 2019 Nov 1;5(11):1605-1613. doi: 10.1001/jamaoncol.2019.2109.
Results Reference
derived
PubMed Identifier
28739540
Citation
Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, Brown JC, Sarwer DB, Troxel AB, Denlinger C, Laudermilk M, Fornash A, DeMichele A, Chodosh LA, Schmitz KH. The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema. Contemp Clin Trials. 2017 Oct;61:63-72. doi: 10.1016/j.cct.2017.07.017. Epub 2017 Jul 21.
Results Reference
derived
PubMed Identifier
27433356
Citation
Dean LT, Kumar A, Kim T, Herling M, Brown JC, Zhang Z, Evangelisti M, Hackley R, Kim J, Cheville A, Troxel AB, Schwartz JS, Schmitz KH. Race or Resource? BMI, Race, and Other Social Factors as Risk Factors for Interlimb Differences among Overweight Breast Cancer Survivors with Lymphedema. J Obes. 2016;2016:8241710. doi: 10.1155/2016/8241710. Epub 2016 Jun 28.
Results Reference
derived

Learn more about this trial

The Women In Steady Exercise Research (WISER) Survivor Trial

We'll reach out to this number within 24 hrs